Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon
Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...
Promising Market Potential and Efficacy of Syndax Pharmaceuticals’ Revumenib Justify Buy Rating
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The ...
The Pharma Letter1d
Syndax shares slide despite pivotal trial success
Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
ENDPOINTS NEWS1d
Syn­dax's menin in­hibitor suc­ceeds in piv­otal tri­al, but in­vestors aren't im­pressed
Syndax Pharmaceuticals' experimental drug revumenib achieved 23% complete remission in NPM1-mutated acute myeloid leukemia ...
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...
Syndax's Revumenib Trial Reports Positive Data In Relapsed/Refractory MNPM1 AML Patients
(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...
FierceBiotech2d
Syndax's small molecule underwhelms investors in midstage acute leukemia trial, sending stock down 22%
While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is ...
bovnews2d
A Promising Cancer Drug and a Troubling Market Response: What’s Next for Syndax (SNDX)?
Despite the promising data, Syndax Pharmaceuticals saw its stock plummet by -21.49% in premarket trading after the latest update on its AUGMENT-101 trial. As of Tuesday morning, the stock was trading ...
Syndax falls after mid-stage data for leukemia drug
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 5, 2024 Syndax Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.98, expectations were $-1.13. Operator: Good day, everyone, and welcome ...